{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.33","value":"3694.5965"},{"groupId":"OG001","spread":"41.80","value":"3807.9179"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected for pharmacokinetic (PK) analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with Relapsed or Refractory Multiple Myeloma (RRMM) received belantamab mafodotin as 2.5 milligram (mg)/kilogram (kg) dose via intravenous (IV) infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG000","title":"Main Study - Part 1: Belantamab Mafodotin 2.5 Milligram/ Kilogram (mg/kg)"},{"description":"Participants with RRMM received belantamab mafodotin as dose of 3.4 mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression.","id":"OG001","title":"Main Study - Part 1: Belantamab Mafodotin 3.4 mg/kg"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic (PK) population included all participants in all treated population from whom at least one PK sample was obtained, analyzed, and was measurable. Only those participants with data available at specified time points have been analyzed.","reportingStatus":"POSTED","timeFrame":"Pre-Dose; End of Infusion (EOI); 1 hour (h), 3 h, 8 h and 24 h post-EOI, Day 8, Day 15 in Cycle 1; Pre-Dose on Cycle 2 Day 1","title":"Part 1: Area Under the Concentration-time Curve During the Dosing Interval (AUC (0-tau)) Following Single Dose Administration of Belantamab Mafodotin (Antibody-drug Conjugate (ADC))","type":"SECONDARY","unitOfMeasure":"Hour*microgram/millilitre (h*ug/mL)"}